Manfred Hauben1,2, Eric Y Hung3, Kelly C Hanretta4, Sripal Bangalore1, Vincenza Snow2. 1. New York University Medical Center, New York, NY, USA. 2. Pfizer, Incorporated, 219 East 42nd Street, New York, NY, 10017, USA. 3. Pfizer, Incorporated, 219 East 42nd Street, New York, NY, 10017, USA. eric.hung@pfizer.com. 4. Mount Sinai School of Medicine, New York, NY, USA.
Abstract
INTRODUCTION: Perflutren microbubble/microsphere ultrasound contrast agents have a black-box warning based on case reports of serious cardiopulmonary events. There have been several subsequent observational safety studies. Large spontaneous reporting databases may help detect/refine signals of rare adverse events that elude other data sources/study designs. OBJECTIVE: The objective of this study was to supplement existing knowledge of the reported safety of perflutren using statistical analysis of spontaneous reports. METHODS: We analyzed information from the US Food and Drug Administration Adverse Event Reporting System using a disproportionality analysis. Analysis of overall reporting for perflutren was supplemented by subset (age, indication) analysis. A signal of disproportionate reporting (SDR) was defined as EB05 >2. RESULTS: Overall, 18/380 Preferred Terms and 1/83 Standardized Medical Queries had SDRs. Most were small (EB05 = 2-4). Back pain and flank pain were the largest SDRs followed by events compatible with signs/symptoms of hypersensitivity. The general pattern of SDRs in the subset analysis was consistent with the overall analysis. Almost all events with SDRs were literally or conceptually labeled. Except for chest pain (higher in the age <65 years subgroup) and back pain (higher in the age ≥65 years subgroup), there were no statistically significant differences between age subsets. Except for the Preferred Terms Pruritus and Urticaria and the narrow Standardized Medical Queries Ventricular tachyarrhythmia, Angioedema, Oropharyngeal allergic conditions, and Hypersensitivity (higher in the stress test subgroup), there were no statistically significant reporting differences between indication subsets. There were no SDRs associated with the major cardiovascular events of death, myocardial infarction/ischemia, angina, arrhythmias, or convulsions in any analysis. CONCLUSIONS: Our combined signal detection/evaluation analysis did not identify SDRs of novel adverse events or major cardiovascular events associated with perflutren ultrasound contrast agents. The negative results for major cardiovascular events extend previous signal evaluation exercises supporting the relative cardiovascular safety of these agents.
INTRODUCTION: Perflutren microbubble/microsphere ultrasound contrast agents have a black-box warning based on case reports of serious cardiopulmonary events. There have been several subsequent observational safety studies. Large spontaneous reporting databases may help detect/refine signals of rare adverse events that elude other data sources/study designs. OBJECTIVE: The objective of this study was to supplement existing knowledge of the reported safety of perflutren using statistical analysis of spontaneous reports. METHODS: We analyzed information from the US Food and Drug Administration Adverse Event Reporting System using a disproportionality analysis. Analysis of overall reporting for perflutren was supplemented by subset (age, indication) analysis. A signal of disproportionate reporting (SDR) was defined as EB05 >2. RESULTS: Overall, 18/380 Preferred Terms and 1/83 Standardized Medical Queries had SDRs. Most were small (EB05 = 2-4). Back pain and flank pain were the largest SDRs followed by events compatible with signs/symptoms of hypersensitivity. The general pattern of SDRs in the subset analysis was consistent with the overall analysis. Almost all events with SDRs were literally or conceptually labeled. Except for chest pain (higher in the age <65 years subgroup) and back pain (higher in the age ≥65 years subgroup), there were no statistically significant differences between age subsets. Except for the Preferred Terms Pruritus and Urticaria and the narrow Standardized Medical Queries Ventricular tachyarrhythmia, Angioedema, Oropharyngeal allergic conditions, and Hypersensitivity (higher in the stress test subgroup), there were no statistically significant reporting differences between indication subsets. There were no SDRs associated with the major cardiovascular events of death, myocardial infarction/ischemia, angina, arrhythmias, or convulsions in any analysis. CONCLUSIONS: Our combined signal detection/evaluation analysis did not identify SDRs of novel adverse events or major cardiovascular events associated with perflutren ultrasound contrast agents. The negative results for major cardiovascular events extend previous signal evaluation exercises supporting the relative cardiovascular safety of these agents.
Authors: Sahar S Abdelmoneim; Mathieu Bernier; Christopher G Scott; Abhijeet Dhoble; Sue Ann C Ness; Mary E Hagen; Stuart Moir; Robert B McCully; Patricia A Pellikka; Sharon L Mulvagh Journal: Circ Cardiovasc Imaging Date: 2010-03-16 Impact factor: 7.792
Authors: Kevin Wei; Sharon L Mulvagh; Lisa Carson; Ravin Davidoff; Ruvin Gabriel; Richard A Grimm; Stephanie Wilson; Lorrie Fane; Charles A Herzog; William A Zoghbi; Rhonda Taylor; Michael Farrar; Farooq A Chaudhry; Thomas R Porter; Waleed Irani; Roberto M Lang Journal: J Am Soc Echocardiogr Date: 2008-10-10 Impact factor: 5.251
Authors: Kevin Wei; Michael L Main; Roberto M Lang; Allan Klein; Stephen Angeli; Carmelo Panetta; Issam Mikati; L Veronica Lee; Jonathan A Bernstein; Masood Ahmad Journal: J Am Soc Echocardiogr Date: 2012-02-23 Impact factor: 5.251
Authors: Melda S Dolan; Simil S Gala; Saritha Dodla; Sahar S Abdelmoneim; Feng Xie; David Cloutier; Michelle Bierig; Sharon L Mulvagh; Thomas R Porter; Arthur J Labovitz Journal: J Am Coll Cardiol Date: 2009-01-06 Impact factor: 24.094